Résumé
Compassionate use allows patients, under strict conditions and in situations of therapeutic impasse, to have access to a medicine before obtaining marketing authorisation. In Europe, the measures in place are not efficient enough, especially in terms of delays. These processes are cumbersome and redundant. There is also a lack of harmonisation at European level, despite regulation (EC) No 726/2004 and the establishment of EUnetHTA. The pandemic has highlighted the weaknesses of existing processes and demonstrated that they can be improved. In Europe and within the five referent countries reforms are being or will be implemented to try to correct this. The EUnetHTA has also been reformed in an attempt to standardise processes. These efforts demonstrate a desire on the part of stakeholders to meet the needs of patients.